Followers | 3344 |
Posts | 84628 |
Boards Moderated | 6 |
Alias Born | 10/05/2005 |
Saturday, March 16, 2024 9:57:53 AM
March 12 2024 - 09:54AM
InvestorsHub NewsWire
Alert
Share On Facebook
Branded Legacy, Inc. Significantly Expands Asset Portfolio and Production Capacity Through Successful Acquisition of Sycamore BioPharma, Inc.
"Company Prepares for Clinical Trials with Esteemed Addition: Dr. Mark T. Hamann, Endowed Chair of Drug Discovery and Biomedical Sciences at the MUSC College of Pharmacy"
Melbourne, FL -- March 12, 2024 -- InvestorsHub NewsWire -- Branded Legacy (OTC.PK: BLEG), Inc., a trailblazing BioTech holdings company, proudly announces the strategic acquisition of Sycamore BioPharma, Inc, a distinguished developer of plant-based pharmaceuticals. This strategic milestone not only fortifies Branded Legacy's standing as a prominent player in the biotech sector but also secures assets exceeding $2 million, along with key personnel crucial for advancing clinical trials following this successful union.
Renowned for its meticulous development of wellness solutions, ranging from gummies to compression sleeves and pain-relieving topical creams, Sycamore BioPharma has earned acclaim as a prolific product developer. The acquisition brings forth over $500,000 in high-quality, ready-to-sell inventory and aligns seamlessly with Branded Legacy's dedication to quality, authenticity, and a commitment to natural ingredients.
David Oswald, CEO at Branded Legacy, Inc., expresses enthusiasm about the acquisition, stating, "Branded Legacy is thrilled to embrace Sycamore BioPharma into our family of companies. This tactical move not only compliments our existing portfolio, but also brings us several steps closer to our goal of achieving FDA approval for several of our pharmaceutical products.."
The acquisition not only opens new markets for Sycamore BioPharma but also provides access to Branded Legacy's extensive network, enhancing the company's ability to connect with consumers, build brand loyalty, and drive sales growth. It was also a crucial step in securing and maintaining a slew of large white label manufacturing and extraction contracts.
Tyler Stone, President of Sycamore Biopharma, Inc., is also enthusiastic about the acquisition stating, "Branded Legacy brings significant strengths in areas where Sycamore BioPharma was seeing significant challenges. Their network and consumer outreach will undoubtedly drive sales growth of our innovative products and we are proud to be a part of the Branded Legacy network of companies."
The collaboration between Branded Legacy and Sycamore BioPharma is poised to unlock synergies across various business facets. Leveraging Branded Legacy's web properties, brand management, and marketing expertise, the integration aims to maximize the reach and impact of Sycamore BioPharma's groundbreaking wellness solutions. Furthermore, the addition of Dr. Mark Hamann, a PHD holding scientist, to Branded Legacy's roster will enhance efforts in developing novel pharmaceuticals and streamline the FDA approval process, particularly in clinical trials.
Dr. Mark T. Hamann, the newly appointed Director of Clinical Trials at Branded Legacy, brings a wealth of expertise as the Charles and Carol Cooper/SmartState Endowed Chair of Drug Discovery and Biomedical Sciences at the Medical University of South Carolina College of Pharmacy. Holding Adjunct appointments with The University of Maryland's Institute of Marine and Environmental Technology and the Bigelow Marine Laboratory in Maine, Dr. Hamann's distinguished career commenced in GMP pharmaceutical manufacturing at Solvay Pharmaceuticals in Baudette, Minnesota.
Throughout his career, Dr. Hamann has authored over 250 scientific papers, reviews, and book chapters, while mentoring over 100 graduate students, postdoctoral fellows, and visiting scholars. Dr. Hamann's graduate studies led to the discovery of the anticancer agent, kahalalide F, which advanced to clinical trials in collaboration with biotech company PharmaMar. Currently serving as an Associate Editor for Biochimica et Biophysica Acta, General Subjects, Dr. Hamann's research group is actively engaged in the isolation, structure determination, and synthesis optimization of natural products and toxins. Their focus on plant and invertebrate microbiomes aligns with Branded Legacy's commitment to sustainable pharmaceutical development.
Dr. Hamann's ongoing projects include the preclinical development of a small pipeline of natural products with potential applications against cancer, emerging infectious diseases, and neuropsychiatric disorders. His extensive experience and dedication to advancing scientific frontiers make him a valuable addition to Branded Legacy's mission to deliver high-quality, scientifically-backed solutions in the biotech industry. Branded Legacy has already begun supplying the Medical University of South Carolina with samples of mitragynine extract in order to build an effective experimental design for addiction mitigation. Although these trials are arduous, Branded Legacy is committed to doing whatever is necessary to support the process and offer these therapies to the patients who need them as quickly as possible
In other company news, Branded Legacy has just completed a move to a significantly larger facility, accommodating the expanding operations and facilitating enhanced capabilities. The move comes in tandem with the acquisition of millions of dollars worth of state-of-the-art scientific and extraction equipment, solidifying Branded Legacy's commitment to staying at the forefront of innovation in the biotech industry.
The new facility not only provides increased space for research and development but also positions Branded Legacy to meet the rising demand for its innovative wellness solutions. The acquisition of advanced scientific and extraction equipment further strengthens the company's technological infrastructure, supporting its endeavors in drug discovery, pharmaceutical development, and the optimization of natural products.
Recent BLEG News
- Branded Legacy, Inc. Reports Significant Net Income of Over $3.8 Million • InvestorsHub NewsWire • 04/16/2024 12:30:00 PM
- Branded Legacy, Inc. To Add $320,000 In Revenue With New White Label Contract • InvestorsHub NewsWire • 04/09/2024 12:30:00 PM
- Branded Legacy, Inc Announces White Label Deal with Kava & Hobbs, LLC for Kava Vape formulation • InvestorsHub NewsWire • 04/04/2024 12:30:00 PM
- Branded Legacy, Inc. Significantly Expands Asset Portfolio and Production Capacity Through Successful Acquisition of Sycamore BioPharma, Inc. • InvestorsHub NewsWire • 03/12/2024 01:54:43 PM
- Shares of this Biotech Holdings Company Up on LOI • AllPennyStocks.com • 02/29/2024 06:10:00 PM
- Branded Legacy, Inc. Strengthens Position in BioTech Industry with Letter of Intent to Purchase Sycamore BioPharma, LLC • InvestorsHub NewsWire • 02/29/2024 01:30:00 PM
- Branded Legacy, Inc. Expands Operations with Move to State of the Art Biotech Facility in Melbourne, FL • InvestorsHub NewsWire • 02/08/2024 01:30:00 PM
- Branded Legacy, Inc. Innovates with Launch of the First 100% Clear Kava-Based Vaping Product on the Market • InvestorsHub NewsWire • 02/06/2024 02:30:00 PM
- Branded Legacy, Inc. Unveils Major Equipment Acquisition Raising Total Assets to $3,787,215.00 • InvestorsHub NewsWire • 01/30/2024 02:25:00 PM
- Branded Legacy, Inc. Reduces Debt by 1.5 Million • InvestorsHub NewsWire • 01/25/2024 01:30:00 PM
- Branded Legacy, Inc. ($BLEG) Announces Reduction in Authorized Share Count to 900M • InvestorsHub NewsWire • 01/23/2024 01:30:00 PM
- Branded Legacy, Inc. (BLEG) Expands Portfolio with Comprehensive Acquisition of MariJ Pharmaceuticals Inc, Including Licenses, Organic Certifications, and Substantial Assets • InvestorsHub NewsWire • 12/05/2023 01:00:00 PM
- Branded Legacy Commences Buyback of 1,000,000 Preferred Class D Shares • InvestorsHub NewsWire • 11/28/2023 12:23:33 PM
- Branded Legacy Signs Letter of Intent to Acquire $6 Million in Assets and Additional Facility Space • InvestorsHub NewsWire • 11/16/2023 12:00:00 PM
- Branded Legacy, Inc. Announces 1.5B Reduction in Authorized Share Count • InvestorsHub NewsWire • 11/09/2023 12:03:15 PM
- Branded Legacy, Inc. Secures $1M Line of Credit, Affirms No Reverse Split, and Previews Upcoming Investor Engagements • InvestorsHub NewsWire • 11/07/2023 12:02:43 PM
- Branded Legacy Takes Bold Step in Strengthening Shareholder Value: Retires 1 Billion Common Shares This Week, With More to Follow • InvestorsHub NewsWire • 10/26/2023 12:30:00 PM
- Rocket Web Development & Design: Navigating the Digital Frontier with Innovation and Excellence • InvestorsHub NewsWire • 10/24/2023 01:00:00 PM
- Branded Legacy, Inc. Has Retired 600 Million Common Shares on Path to Retire 2 Billion by November 2023 • InvestorsHub NewsWire • 10/19/2023 12:00:00 PM
- Branded Legacy Completes Acquisition of The Alcannabist, Signifying Business Expansion • InvestorsHub NewsWire • 10/10/2023 12:25:00 PM
- Total Refinement Solutions LLC Transitions to Royal Biotek Under $BLEG Portfolio • InvestorsHub NewsWire • 10/05/2023 12:18:33 PM
- Branded Legacy Expands Facility to 11,000 Sqft, Extends LOI for Acquisition of The Alcannabist LLC • InvestorsHub NewsWire • 10/03/2023 12:00:00 PM
- Branded Legacy Inc. Unveils Exciting Q4 2023 Milestones and Forges Ahead with Key Partnerships • InvestorsHub NewsWire • 09/28/2023 02:44:40 PM
- Branded Legacy Inc. Invests Heavily in Innovation and Growth with $540,000 Expansion • InvestorsHub NewsWire • 09/26/2023 02:37:45 PM
- Branded Legacy and Novus Partner to Develop Plant-Based Meds for Health Plans • InvestorsHub NewsWire • 09/12/2023 11:30:00 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM